| High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults. | |
| | |
MedLine Citation:
|
PMID: 20121571 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Epstein-Barr virus (EBV) and cytomegalovirus reactivations are frequent complications of hematopoeitic allogeneic stem cell transplantation (SCT) because of a lack of T cell control after immunosuppression. Early diagnosis of reactivation and subsequent preemptive therapy relies on frequent viral load measurement. Additional virus-specific T cell reconstitution data could improve the predictive value of viral load detection for viral complications after transplantation. Here, we studied perforin expression in CD8(+) T cells as a measure of cytotoxic T cell capacity in relation to the occurrence of viral reactivation. METHODS: In a prospective study, we monitored 40 patients during the first 3 months after transplantation and measured viral loads in combination with intracellular perforin expression in CD8(+) T cells. RESULTS: Median perforin expression in CD8(+) T cells throughout follow-up was higher in patients with viral reactivations than in patients without viral reactivations (4.9% vs 2.3%; P = .001). The median percentage of perforin-expressing CD8(+) T cells in patients with high viral reactivations exceeding 1000 copies/mL (10.7%) was statistically significantly higher than that in patients with minor reactivations of 50-1000 copies (4.0%), that in patients with detectable EBV loads that did not exceed the detection limit of 50 copies/mL (2.9%), and that in patients without reactivations (0.8%). Patients with high viral reactivations reached a high percentage of perforin-expressing CD8(+) T cells (>10.2%) more often and faster than did patients with low viral loads (1000 copies/mL) or without viral reactivations. High perforin expression preceded high viral loads. CONCLUSION: Perforin-expressing CD8(+) T cells may be useful as an easy-to-measure prognostic marker for identifying patients at risk for severe viral reactivation very soon after SCT. |
| | |
Authors:
|
F L Pietersma; S van Dorp; R Jacobi; L Ran; N M Nanlohy; R Schuurman; M C Minnema; E Meijer; D van Baarle |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 50 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-08 Completed Date: 2010-04-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 717-25 Citation Subset: IM |
Affiliation:
|
Department of Immunology, University Medical Center Utrecht, the Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged CD8-Positive T-Lymphocytes / immunology* Cytomegalovirus / immunology Cytomegalovirus Infections / diagnosis, immunology* Epstein-Barr Virus Infections / diagnosis, immunology* Female Herpesvirus 4, Human / immunology Humans Male Middle Aged Perforin / biosynthesis* Prognosis Retrospective Studies Stem Cell Transplantation / adverse effects* Virus Activation / immunology* Young Adult |
| Chemical | |
Reg. No./Substance:
|
126465-35-8/Perforin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Infectious Mononucleosis in University Students in the United Kingdom: Evaluation of the Clinical Fe...
Next Document: Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household tr...